Home > Products > B cell lymphoma BCL1 Idiotype & CD64 > Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Triple Body)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Triple Body)  (TRIB-001)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-B cell lymphoma BCL1 Idiotype antibody are both extended with the scFv fragment from an anti-CD64 antibody. This BsAb can retarget immune cells to tumor cells. It is designed for the research of B cell lymphoma therapy.

Specifications

Targets
B cell lymphoma BCL1 Idiotype & CD64
Type
Triple Body
Species Reactivity
Mouse
Target 1
B cell lymphoma BCL1 Idiotype
Host Animal 1
Rat
Target 2
CD64
Host Animal 2
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
B cell lymphoma

Targets

Target 1
B cell lymphoma BCL1 Idiotype
Alternative Names
B cell lymphoma BCL1 Idiotype; B cell lymphoma; BCL1; Idiotype; Id; 31D1; 32D1
Target 2
CD64
Gene ID
UniProt ID
Alternative Names
FcγRI; FCGR1A; Fc fragment of IgG, high affinity Ia, receptor (CD64); CD64; FCRI; CD64A; IGFR1; high affinity immunoglobulin gamma Fc receptor I; fcgammaRIa; Fc-gamma RI; fc-gamma RIA; Fc gamma receptor; IgG Fc receptor I; Fc-gamma receptor I A1; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCGR1B, FCGR1C

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Triple Body) (TRIB-001). Click the button below to contact us or submit your feedback about this product.

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Online Inquiry

24x7 Service quality
USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: